The Board of Directors of Morepen Laboratories Limited approved the investment proposed by Corinth Group Corinth a global private investment Group fwww.corinthinvest.coml headquartered in Switzerland to the extent of USD 32.50 million in the parent company Morepen Laboratories Limited Morepen or The Company out of a total USD 100 million investment in the promoter group subject to approval of the shareholders and other regulatory bodies.Following shareholder and regulatory approval Corinth would be allotted 58.50 million new Equity shares on preferential basis. This shareholding would equate to 9.41 equity stake in the Company on a fully expanded capital base. The balance USD 67.50 million would be in the promoter group companies. The Board of Directors has also approved allotment of 50 million fresh Equity Shares to the promoter group at a price determined by the Securities and Exchange Board of India SEBI pricing formula for preferential issuances in lieu of the 98.50 million unsubscribed warrants issued in the last financial year which lapsed due to technical reasons. While the new allotment would be at Rs 38 per share which will be 52 higher than the earlier price of Rs 25 per for each warrant. After subscription of all the warrants the promoters stake in the company would go up to 44.28 from 34.54 on a fully diluted basis.Accordingly the Total Fund Infusion in Morepen Laboratories Ltd including investor funds and promoters equity will be Rs. 565 croces. The funds would be used inThe expansionscaling up of the companys RD centrefacilities to meet the significantly enhanced Active Pharmaceutical Ingredient API demand a market size of US40 billion that Morepen has in the pipeline for the next 3 yearsSetting up new USFDA standard API plant to meet the significant ramp up in scale and pipeline the company is working onEstablishing a world class facility for Finished Dosages as per USFDA standards at Morepens pharma complex in Baddi Himachal Pradesh to cater to highly sophisticatedregulated markets such as the USA and JapanInvestment into world class diagnostics facilities including the manufacture of critical inputscomponentsenzymes to meet regulated market standards. India is seeing an exponential jump in household spend on Point of CareHome Diagnostics and Oxygen Concentrators and other life support systems with demand currently outstripping supplyInvestment in new products and brands under the Dr Morepen umbrella an existing household brand to leverage its pan India distributionsupply chain and exponential growth in online salesInvestment in new age Personal CareSkin Care brands Gubb and Happier that are seeing exponential online sales as well as to leverage our Pan India pharmacyretail chain network to significantly scale up distribution.We are delighted to partner with the well-respected institution Corinth Group ot Switzerland who have a dedicated fund for emerging markets more particularly India market and healthcare. The Rs 750 crores investment by Corinth in the Morepen Group affirms our leadership position in API. Point of Care Diagnostics OTC and the faith global investors have in our growth potential and future says Mr. Sushi Suri Chairman and Manging Director Morepen Labs Ltd. NSE MOREPENLAB BSE 500288Sir Christopher Pissarides Chairman of Corinth Groups Advisory Board and Nobel Prize laureate 2010 In Economics said The investment into Morepen follows from our increased focus on emerging markets and in particular the health and pharmaceutical industry. India is a key global market with significant growth opportunity and we look forward to working with management to help the business develop while catering to a rapidly growing sector.Mr. Andreas Matsas CEO of the Corinth Capital Fund www.corinthcapitalfund.com said We are bullish about the Indian market and have already started the process of setting up a dedicated full-service office in Delhi India through a wholly owned subsidiary which will be functional in May 2021. We are actively working towards setting up an AIF in line with Indian regulatory requirements to cater to the Indian market. Our Investment into Morepen Group establishes Corinths long-term commitment to the Indian market with ongoing investments ot another USD 200 million in the Agri and Logistics sector undergoing due diligence.Mr. Martin Walter Model Head of Credit Committee of the Corinth Group of Companies said Morepen is a listed research -based organisation with a 35-year heritage USFDA approved facilities and is a business that is closely aligned to our ethos and investment strategy giving us access to a rapidly evolving and growing healthcare sector in India. The business exports API to over eighty countries worldwide with regulatory approvals from most markets including the USA Europe Japan and Korea. In the domestic market Morepen is a leader In the point of care medical diagnostics market through is brand. Dr. Morepen. With changing lifestyles and more importantly the recent Covidcrisis home diagnostics have and will continue to be a core part of peoples lives. It is estimated that global home diagnostics and point of care spends have gone up 20-30 times over the past year and Morepen is well positioned to cater to this growing global demand. As the personal health and fitness trend continues to gather pace. Dr. Morepens brand presence in the OTC and nutritional segment differentiates the business from others.
🔍 Key Information
📄
Tender Reference No.
462021650
📅
Publication Date
30 Apr 2021
🌐
Sector
Banking, Finance, Insurance and Securities (BFIS)
📝
Notice Type
News
📍
Location
India
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.